News – Page 1157 – Endpoints News

Versant’s global biotech team is reloading with $350M-plus fund

9 years ago

Cardio event forces FDA to halt a Penn PhII study for multiple myeloma

9 years ago

It’s Endpoints News' issue #100: The new daily biotech pub now has a little history

9 years ago

Cardio drug at The Medicines Co gets the heave-ho. (But they prefer PCSK9 anyway.)

9 years ago

Therapix Bio in the hunt for $12M micro IPO; Progenics bags $50M loan; Juno isn't going anywhere, for now

9 years ago

Roche flags early success for Tecentriq combos, hustles into PhIIIs

9 years ago

Public combat over US drug prices centers on Prop 61 as rhetoric heats up to fever pitch

9 years ago

Poised to launch a new drug for SMA, Biogen and Ionis shares jump on more promising PhIII data

9 years ago

Syncona, CRUK and BACIT join forces to create a $1.2B biotech investment powerhouse

9 years ago

In a squeaker, FDA AdComm votes for an OK of Cempra’s antibiotic

9 years ago

Alnylam spells out just why it scrapped revusiran following patient deaths; Innocoll shares plunge on PhIII flops

9 years ago

Hillary Clinton's War on Pharma II; A call for common sense reporting on Alzheimer's R&D

9 years ago

Sanofi jumps into a pivotal study for next-gen Pompe drug

9 years ago

Nestlé invests $145M in Aimmune’s food allergy R&D work, taking the head seat at the deal table

9 years ago

Clinton’s chief strategist urged tough drug stance that aimed straight for the "cost pain point”

9 years ago

FDA officials: There was “no scientific basis” for Duchenne drug OK as Sarepta complained of “dire financial” ...

9 years ago

Celyad chief blasts Cellectis’ CEO Choulika, claiming he lied about CAR-T patent

9 years ago

SEC subpoenaes BioMarin in drisapersen probe; Job hunting? The FDA has hundreds of open positions

9 years ago

The losers are piling up after today’s big ASH abstract drop

9 years ago

Spark Therapeutics shares slide after a setback on its hemophilia gene therapy study

9 years ago

Investigators sound a safety alarm after 2 patients die of heart condition following checkpoint combo

9 years ago

Merck can’t prove its Alzheimer’s drug works, yet, but it did just explain why it’s spending a fortune on PhIII

9 years ago

Severe adverse events mar the end of Roche’s PhIII for ‘breakthrough’ hemophilia drug

9 years ago

PTC sees higher regulatory risk in fight to keep its Duchenne drug on the European market

9 years ago

First page Previous page 1154 1155 115611571158 1159 1160 Next page Last page